Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors

Authors

Blessie Elizabeth Nelson
Funda Meric-Bernstam

Publication Date

1-29-2024

Journal

Annual Reviews of Medicine

DOI

10.1146/annurev-med-071322-065903

PMID

37758237

Abstract

Antibody-drug conjugates (ADCs) have become the cornerstone of effective therapeutics in solid and hematological malignancies by harnessing potent cytotoxic payloads with targeted tumoricidal delivery. Since the monumental shift occurred with HER2-targeted ADCs, the discovery of the TROP2 antigen has revolutionized the landscape of ADC development. Moving beyond the traditional ADC design, multiple novel ADCs have successfully shaped and improved survival outcomes in patients with various tumor histologies. Here we review and contrast the clinical impact of the well-known TROP2 ADCs currently in clinical use. We also shed light on upcoming investigational TROP2 ADCs showing promise with novel ADC platforms.

Keywords

Humans, Immunoconjugates, Neoplasms, Antineoplastic Agents, Hematologic Neoplasms

Published Open-Access

yes

Recommended Citation

Blessie Elizabeth Nelson and Funda Meric-Bernstam, "Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors" (2024). Faculty, Staff and Student Publications. 4819.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4819